מדינה: ארמניה
שפה: אנגלית
מקור: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
ceftriaxone (ceftriaxone sodium)
Anfarm Hellas S.A.
J01DD04
ceftriaxone (ceftriaxone sodium)
1000mg
powder and solvent for solution for i/m injection
(1) glass vial and solvent in ampoule 3.5ml
Prescription
Registered
2021-03-17
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT MARION Powder and Solvent for solution for I.M. injection 1g MARION Powder for solution for injection or infusion 1g 2. QUALITATIVE AND QUANTITATIVE COMPOSITION MARION Powder and Solvent for solution for I.M. injection 1g: Each vial contains ceftriaxone sodium equivalent to ceftriaxone 1g. Each ampoule of solvent contains lidocaine hydrochloride 35mg, water for injection qs 3.5ml MARION Powder for solution for injection or infusion 1g: Each vial contains ceftriaxone sodium equivalent to ceftriaxone 1g 3. PHARMACEUTICAL FORM Powder and solvent for solution for I.M. injection Powder for solution for injection or infusion 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Ceftriaxone is indicated for the treatment of the following infections in adults and children including term neonates (from birth): • Bacterial Meningitis • Community acquired pneumonia • Hospital acquired pneumonia • Acute otitis media • Intra-abdominal infections • Complicated urinary tract infections (including pyelonephritis) • Infections of bones and joints • Complicated skin and soft tissue infections • Gonorrhoea • Syphilis • Bacterial endocarditis Ceftriaxone may be used: For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age. For Pre-operative prophylaxis of surgical site infections. In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Treatment may be started before the results of susceptibility tests are known. Ceftriaxone should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within קרא את המסמך השלם